A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

NCT02388594 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

DRUG: ZFN Modified CD4+ T Cells
DRUG: Cyclophosphamide

Sponsor

University of Pennsylvania

Collaborators

[object Object]